Loading…
Presenting features and treatment outcomes of chronic lymphocytic leukaemia in a resource poor Southern Nigeria
Chronic lymphocytic leukaemia is a relatively common haematological malignancy affecting older adults, accounting for about 20% of haematological malignancies in Nigeria. Diagnosis of this disease depends on the demonstration of clonal lymphocytosis > 5 × 109/L with a characteristic immunophenoty...
Saved in:
Published in: | Malawi medical journal 2019-06, Vol.31 (2), p.144-149 |
---|---|
Main Authors: | , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c372t-827d82e69bc23f2c118db893ad41e6529f588c9de62a02204777dd0439f87eb73 |
---|---|
cites | |
container_end_page | 149 |
container_issue | 2 |
container_start_page | 144 |
container_title | Malawi medical journal |
container_volume | 31 |
creator | Madu, Anazoeze Jude Korubo, Kaladada Okoye, Augustine Ajuba, Ifeoma Duru, Augustine N Ugwu, Angela O Nnachi, Oji Okoye, Helen Chioma |
description | Chronic lymphocytic leukaemia is a relatively common haematological malignancy affecting older adults, accounting for about 20% of haematological malignancies in Nigeria. Diagnosis of this disease depends on the demonstration of clonal lymphocytosis > 5 × 109/L with a characteristic immunophenotypic pattern amidst other clinical and laboratory features.
To determine the predominant clinical and laboratory features of CLL at presentation and their relationship with patient survival. This study also aims at examining the relationship between treatment protocol and outcome.
This is a retrospective study with 8 years data (2010-2018) collected from four different centers. Data was analyzed using SPSS 20.0.
There were a total of 97 cases, with a male: female ratio of 1.1:1. The median age at presentation was 59 years. Approximately 55% of the patients presented at Binet stage C, with splenomegaly in 93.2% and 78% were anaemic. The mean white cell count was 137.9 ± 14.7 × 109/L, with a median absolute lymphocyte count of 86 × 109/L. The commonest treatment regimen was chlorambucil and prednisolone and males had a superior response. The number of chemotherapy cycles, serum alkaline phosphatase and aspartate transaminase correlated positively with duration of survival. Mortality rate over the five year period was 14.3%.
CLL was found to present in younger patients when compared to previous studies with a median age of 57 years at diagnosis. Our study showed a slight female preponderance and better response to therapy in males. Majority of the patients presented in Binet stage C and were treated with chlorambucil-based drug combinations compared to more current treatment with Fludarabine-based combinations. A high serum alanine transaminase and alkaline phosphatase was found to positively correlate with survival amongst this patient population. |
doi_str_mv | 10.4314/mmj.v31i2.7 |
format | article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6698622</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2281127732</sourcerecordid><originalsourceid>FETCH-LOGICAL-c372t-827d82e69bc23f2c118db893ad41e6529f588c9de62a02204777dd0439f87eb73</originalsourceid><addsrcrecordid>eNpdUU2LFDEQDaK4H3ryLgEvwjJjUunuJBdBll0VllVQzyGTrp7J2EnGpHth_v1m3HVQT_X16vGqHiGvOFs2gjfvQtgu7wT3sJRPyCnXul1IkOzpMe_ghJyVsmWs1Uy2z8lJXWtBNeqUpK8ZC8bJxzUd0E5zLamNPZ1yrUKd0DRPLoXaTgN1m5yid3Tch90muf10yHH-aTF4S32kllaCNGeHdJdSpt_q9gZzpLd-jdnbF-TZYMeCLx_jOflxffX98tPi5svHz5cfbhZOSJgWCmSvADu9ciAGcJyrfqW0sH3DsWtBD61STvfYgWUArJFS9j1rhB6UxJUU5-T9A-9uXgXsXT0k29Hssg82702y3vw7iX5j1unOdJ1WHUAlePtIkNOvGctkgi8Ox9FGTHMxAIpzkFIcoG_-g27rB2I9z0DbiEYKwURFXTygXE6lZByOYjgzByNNNdL8NtIc9L_-W_8R-8c5cQ8DO5x2</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2543473303</pqid></control><display><type>article</type><title>Presenting features and treatment outcomes of chronic lymphocytic leukaemia in a resource poor Southern Nigeria</title><source>Publicly Available Content (ProQuest)</source><source>PubMed Central</source><creator>Madu, Anazoeze Jude ; Korubo, Kaladada ; Okoye, Augustine ; Ajuba, Ifeoma ; Duru, Augustine N ; Ugwu, Angela O ; Nnachi, Oji ; Okoye, Helen Chioma</creator><creatorcontrib>Madu, Anazoeze Jude ; Korubo, Kaladada ; Okoye, Augustine ; Ajuba, Ifeoma ; Duru, Augustine N ; Ugwu, Angela O ; Nnachi, Oji ; Okoye, Helen Chioma</creatorcontrib><description>Chronic lymphocytic leukaemia is a relatively common haematological malignancy affecting older adults, accounting for about 20% of haematological malignancies in Nigeria. Diagnosis of this disease depends on the demonstration of clonal lymphocytosis > 5 × 109/L with a characteristic immunophenotypic pattern amidst other clinical and laboratory features.
To determine the predominant clinical and laboratory features of CLL at presentation and their relationship with patient survival. This study also aims at examining the relationship between treatment protocol and outcome.
This is a retrospective study with 8 years data (2010-2018) collected from four different centers. Data was analyzed using SPSS 20.0.
There were a total of 97 cases, with a male: female ratio of 1.1:1. The median age at presentation was 59 years. Approximately 55% of the patients presented at Binet stage C, with splenomegaly in 93.2% and 78% were anaemic. The mean white cell count was 137.9 ± 14.7 × 109/L, with a median absolute lymphocyte count of 86 × 109/L. The commonest treatment regimen was chlorambucil and prednisolone and males had a superior response. The number of chemotherapy cycles, serum alkaline phosphatase and aspartate transaminase correlated positively with duration of survival. Mortality rate over the five year period was 14.3%.
CLL was found to present in younger patients when compared to previous studies with a median age of 57 years at diagnosis. Our study showed a slight female preponderance and better response to therapy in males. Majority of the patients presented in Binet stage C and were treated with chlorambucil-based drug combinations compared to more current treatment with Fludarabine-based combinations. A high serum alanine transaminase and alkaline phosphatase was found to positively correlate with survival amongst this patient population.</description><identifier>ISSN: 1995-7262</identifier><identifier>EISSN: 1995-7270</identifier><identifier>EISSN: 1995-7262</identifier><identifier>DOI: 10.4314/mmj.v31i2.7</identifier><identifier>PMID: 31452848</identifier><language>eng</language><publisher>Malawi: University of Malawi</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Alkaline Phosphatase - blood ; Antineoplastic Agents, Alkylating ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Aspartate Aminotransferases - blood ; Chlorambucil - therapeutic use ; Female ; Hematology ; Humans ; Laboratories ; Leukemia ; Leukemia, Lymphocytic, Chronic, B-Cell - blood ; Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy ; Leukemia, Lymphocytic, Chronic, B-Cell - mortality ; Male ; Males ; Middle Aged ; Nigeria - epidemiology ; Original Research ; Patients ; Phosphatase ; Retrospective Studies ; Survival Rate ; Treatment Outcome</subject><ispartof>Malawi medical journal, 2019-06, Vol.31 (2), p.144-149</ispartof><rights>2019. This work is published under https://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2019 The College of Medicine and the Medical Association of Malawi. 2019</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c372t-827d82e69bc23f2c118db893ad41e6529f588c9de62a02204777dd0439f87eb73</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6698622/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2543473303?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25752,27923,27924,37011,37012,44589,53790,53792</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31452848$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Madu, Anazoeze Jude</creatorcontrib><creatorcontrib>Korubo, Kaladada</creatorcontrib><creatorcontrib>Okoye, Augustine</creatorcontrib><creatorcontrib>Ajuba, Ifeoma</creatorcontrib><creatorcontrib>Duru, Augustine N</creatorcontrib><creatorcontrib>Ugwu, Angela O</creatorcontrib><creatorcontrib>Nnachi, Oji</creatorcontrib><creatorcontrib>Okoye, Helen Chioma</creatorcontrib><title>Presenting features and treatment outcomes of chronic lymphocytic leukaemia in a resource poor Southern Nigeria</title><title>Malawi medical journal</title><addtitle>Malawi Med J</addtitle><description>Chronic lymphocytic leukaemia is a relatively common haematological malignancy affecting older adults, accounting for about 20% of haematological malignancies in Nigeria. Diagnosis of this disease depends on the demonstration of clonal lymphocytosis > 5 × 109/L with a characteristic immunophenotypic pattern amidst other clinical and laboratory features.
To determine the predominant clinical and laboratory features of CLL at presentation and their relationship with patient survival. This study also aims at examining the relationship between treatment protocol and outcome.
This is a retrospective study with 8 years data (2010-2018) collected from four different centers. Data was analyzed using SPSS 20.0.
There were a total of 97 cases, with a male: female ratio of 1.1:1. The median age at presentation was 59 years. Approximately 55% of the patients presented at Binet stage C, with splenomegaly in 93.2% and 78% were anaemic. The mean white cell count was 137.9 ± 14.7 × 109/L, with a median absolute lymphocyte count of 86 × 109/L. The commonest treatment regimen was chlorambucil and prednisolone and males had a superior response. The number of chemotherapy cycles, serum alkaline phosphatase and aspartate transaminase correlated positively with duration of survival. Mortality rate over the five year period was 14.3%.
CLL was found to present in younger patients when compared to previous studies with a median age of 57 years at diagnosis. Our study showed a slight female preponderance and better response to therapy in males. Majority of the patients presented in Binet stage C and were treated with chlorambucil-based drug combinations compared to more current treatment with Fludarabine-based combinations. A high serum alanine transaminase and alkaline phosphatase was found to positively correlate with survival amongst this patient population.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Alkaline Phosphatase - blood</subject><subject>Antineoplastic Agents, Alkylating</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Aspartate Aminotransferases - blood</subject><subject>Chlorambucil - therapeutic use</subject><subject>Female</subject><subject>Hematology</subject><subject>Humans</subject><subject>Laboratories</subject><subject>Leukemia</subject><subject>Leukemia, Lymphocytic, Chronic, B-Cell - blood</subject><subject>Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy</subject><subject>Leukemia, Lymphocytic, Chronic, B-Cell - mortality</subject><subject>Male</subject><subject>Males</subject><subject>Middle Aged</subject><subject>Nigeria - epidemiology</subject><subject>Original Research</subject><subject>Patients</subject><subject>Phosphatase</subject><subject>Retrospective Studies</subject><subject>Survival Rate</subject><subject>Treatment Outcome</subject><issn>1995-7262</issn><issn>1995-7270</issn><issn>1995-7262</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><recordid>eNpdUU2LFDEQDaK4H3ryLgEvwjJjUunuJBdBll0VllVQzyGTrp7J2EnGpHth_v1m3HVQT_X16vGqHiGvOFs2gjfvQtgu7wT3sJRPyCnXul1IkOzpMe_ghJyVsmWs1Uy2z8lJXWtBNeqUpK8ZC8bJxzUd0E5zLamNPZ1yrUKd0DRPLoXaTgN1m5yid3Tch90muf10yHH-aTF4S32kllaCNGeHdJdSpt_q9gZzpLd-jdnbF-TZYMeCLx_jOflxffX98tPi5svHz5cfbhZOSJgWCmSvADu9ciAGcJyrfqW0sH3DsWtBD61STvfYgWUArJFS9j1rhB6UxJUU5-T9A-9uXgXsXT0k29Hssg82702y3vw7iX5j1unOdJ1WHUAlePtIkNOvGctkgi8Ox9FGTHMxAIpzkFIcoG_-g27rB2I9z0DbiEYKwURFXTygXE6lZByOYjgzByNNNdL8NtIc9L_-W_8R-8c5cQ8DO5x2</recordid><startdate>20190601</startdate><enddate>20190601</enddate><creator>Madu, Anazoeze Jude</creator><creator>Korubo, Kaladada</creator><creator>Okoye, Augustine</creator><creator>Ajuba, Ifeoma</creator><creator>Duru, Augustine N</creator><creator>Ugwu, Angela O</creator><creator>Nnachi, Oji</creator><creator>Okoye, Helen Chioma</creator><general>University of Malawi</general><general>The Medical Association Of Malawi</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20190601</creationdate><title>Presenting features and treatment outcomes of chronic lymphocytic leukaemia in a resource poor Southern Nigeria</title><author>Madu, Anazoeze Jude ; Korubo, Kaladada ; Okoye, Augustine ; Ajuba, Ifeoma ; Duru, Augustine N ; Ugwu, Angela O ; Nnachi, Oji ; Okoye, Helen Chioma</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c372t-827d82e69bc23f2c118db893ad41e6529f588c9de62a02204777dd0439f87eb73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Alkaline Phosphatase - blood</topic><topic>Antineoplastic Agents, Alkylating</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Aspartate Aminotransferases - blood</topic><topic>Chlorambucil - therapeutic use</topic><topic>Female</topic><topic>Hematology</topic><topic>Humans</topic><topic>Laboratories</topic><topic>Leukemia</topic><topic>Leukemia, Lymphocytic, Chronic, B-Cell - blood</topic><topic>Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy</topic><topic>Leukemia, Lymphocytic, Chronic, B-Cell - mortality</topic><topic>Male</topic><topic>Males</topic><topic>Middle Aged</topic><topic>Nigeria - epidemiology</topic><topic>Original Research</topic><topic>Patients</topic><topic>Phosphatase</topic><topic>Retrospective Studies</topic><topic>Survival Rate</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Madu, Anazoeze Jude</creatorcontrib><creatorcontrib>Korubo, Kaladada</creatorcontrib><creatorcontrib>Okoye, Augustine</creatorcontrib><creatorcontrib>Ajuba, Ifeoma</creatorcontrib><creatorcontrib>Duru, Augustine N</creatorcontrib><creatorcontrib>Ugwu, Angela O</creatorcontrib><creatorcontrib>Nnachi, Oji</creatorcontrib><creatorcontrib>Okoye, Helen Chioma</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content (ProQuest)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Malawi medical journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Madu, Anazoeze Jude</au><au>Korubo, Kaladada</au><au>Okoye, Augustine</au><au>Ajuba, Ifeoma</au><au>Duru, Augustine N</au><au>Ugwu, Angela O</au><au>Nnachi, Oji</au><au>Okoye, Helen Chioma</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Presenting features and treatment outcomes of chronic lymphocytic leukaemia in a resource poor Southern Nigeria</atitle><jtitle>Malawi medical journal</jtitle><addtitle>Malawi Med J</addtitle><date>2019-06-01</date><risdate>2019</risdate><volume>31</volume><issue>2</issue><spage>144</spage><epage>149</epage><pages>144-149</pages><issn>1995-7262</issn><eissn>1995-7270</eissn><eissn>1995-7262</eissn><abstract>Chronic lymphocytic leukaemia is a relatively common haematological malignancy affecting older adults, accounting for about 20% of haematological malignancies in Nigeria. Diagnosis of this disease depends on the demonstration of clonal lymphocytosis > 5 × 109/L with a characteristic immunophenotypic pattern amidst other clinical and laboratory features.
To determine the predominant clinical and laboratory features of CLL at presentation and their relationship with patient survival. This study also aims at examining the relationship between treatment protocol and outcome.
This is a retrospective study with 8 years data (2010-2018) collected from four different centers. Data was analyzed using SPSS 20.0.
There were a total of 97 cases, with a male: female ratio of 1.1:1. The median age at presentation was 59 years. Approximately 55% of the patients presented at Binet stage C, with splenomegaly in 93.2% and 78% were anaemic. The mean white cell count was 137.9 ± 14.7 × 109/L, with a median absolute lymphocyte count of 86 × 109/L. The commonest treatment regimen was chlorambucil and prednisolone and males had a superior response. The number of chemotherapy cycles, serum alkaline phosphatase and aspartate transaminase correlated positively with duration of survival. Mortality rate over the five year period was 14.3%.
CLL was found to present in younger patients when compared to previous studies with a median age of 57 years at diagnosis. Our study showed a slight female preponderance and better response to therapy in males. Majority of the patients presented in Binet stage C and were treated with chlorambucil-based drug combinations compared to more current treatment with Fludarabine-based combinations. A high serum alanine transaminase and alkaline phosphatase was found to positively correlate with survival amongst this patient population.</abstract><cop>Malawi</cop><pub>University of Malawi</pub><pmid>31452848</pmid><doi>10.4314/mmj.v31i2.7</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1995-7262 |
ispartof | Malawi medical journal, 2019-06, Vol.31 (2), p.144-149 |
issn | 1995-7262 1995-7270 1995-7262 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6698622 |
source | Publicly Available Content (ProQuest); PubMed Central |
subjects | Adult Aged Aged, 80 and over Alkaline Phosphatase - blood Antineoplastic Agents, Alkylating Antineoplastic Combined Chemotherapy Protocols - therapeutic use Aspartate Aminotransferases - blood Chlorambucil - therapeutic use Female Hematology Humans Laboratories Leukemia Leukemia, Lymphocytic, Chronic, B-Cell - blood Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy Leukemia, Lymphocytic, Chronic, B-Cell - mortality Male Males Middle Aged Nigeria - epidemiology Original Research Patients Phosphatase Retrospective Studies Survival Rate Treatment Outcome |
title | Presenting features and treatment outcomes of chronic lymphocytic leukaemia in a resource poor Southern Nigeria |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T02%3A36%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Presenting%20features%20and%20treatment%20outcomes%20of%20chronic%20lymphocytic%20leukaemia%20in%20a%20resource%20poor%20Southern%20Nigeria&rft.jtitle=Malawi%20medical%20journal&rft.au=Madu,%20Anazoeze%20Jude&rft.date=2019-06-01&rft.volume=31&rft.issue=2&rft.spage=144&rft.epage=149&rft.pages=144-149&rft.issn=1995-7262&rft.eissn=1995-7270&rft_id=info:doi/10.4314/mmj.v31i2.7&rft_dat=%3Cproquest_pubme%3E2281127732%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c372t-827d82e69bc23f2c118db893ad41e6529f588c9de62a02204777dd0439f87eb73%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2543473303&rft_id=info:pmid/31452848&rfr_iscdi=true |